Connect with us

Health

AstraZeneca to Showcase Breakthrough Respiratory Portfolio at ATS 2024 Conference

Published

5 months ago

on

Times News Global Featured Image

AstraZeneca will present new clinical and real-world data at the upcoming American Thoracic Society (ATS) International Conference 2024, held in San Diego. The event will focus on the company’s innovative respiratory portfolio, addressing unmet needs in diseases such as COPD, severe asthma, and EGPA.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, highlighted the company’s commitment to advancing treatments beyond symptom control towards potential disease modification and cure. The COURSE Phase IIa data on tezepelumab in COPD patients with various profiles will be a key focus of the conference.

Ruud Dobber, Executive Vice President and President of AstraZeneca’s BioPharmaceuticals Business Unit, emphasized the importance of the broad pipeline and inhaled and biologic medicines in transforming respiratory care.

Key presentations at ATS 2024 include insights on Tezspire, investigating inhaled triple therapy Breztri’s impact on cardiopulmonary outcomes, and Fasenra’s role in reducing oral glucocorticoid use in patients with EGPA.

AstraZeneca will also present data on Airsupra, a first-in-class anti-inflammatory rescue therapy for asthma, and early science exploring new modalities for moderate-severe add-on treatments.

Rachel Adams

Times News Global is a dynamic online news portal dedicated to providing comprehensive and up-to-date news coverage across various domains including politics, business, entertainment, sports, security, features, opinions, environment, education, technology and global. affairs. Our commitment lies in sharing news that is based on factual accuracy, credibility, verifiability, authority and depth of research. We pride ourselves on being a distinctive media organization, guided by the principles enshrined in Article 19 of the Universal Declaration of Human Rights. Made up of a team of ordinary people driven by an unwavering dedication to uncovering the truth, we publish news without bias or intimidation.